Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer
Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer
Transperineal biopsy improves prostate cancer detection
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy
EAU 2025: Updates in NMIBC
Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Higher visceral fat linked to reduced overall survival in older adults with newly diagnosed gastrointestinal malignancies
Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC
Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC
ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib
Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC
Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option